Pulmonary Fibrosis

Latest News
July 9th 2025

Metabolites With Potential Role in IPF Identified by Genome-Wide Association Study

June 30th 2025

Gene Variants Linked With Survival Outcomes in IPF

June 28th 2025

AI Identifies Possible New Therapy for IPF

June 27th 2025

Differentially Expressed Genes May Serve as IPF Biomarkers

June 26th 2025

Deep Learning Biomarkers Help Uncover ENV-101 Treatment Effects in IPF

Advancing IPF Care: New Evidence and Economic Considerations in Treatment Decision-Making

Learn about the clinical and economic burden of idiopathic and progressive pulmonary fibrosis; the need for earlier diagnosis and improved care coordination; and emerging therapies that may close treatment gaps.

AJMC Peer Exchange logo displayed on a blue geometric background with layered diamond shapes.
Video Series
View All
November 8th 2024

Impact of Treatment Delays on Patient Outcomes

October 31st 2024

Overcoming Treatment Barriers: Strategies for Success

October 24th 2024

Clinical Presentation and Risk Factors

October 24th 2024

Impact of Comorbidities on IPF Management

October 24th 2024

Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection

October 17th 2024

Impact of IPF on Quality of Life and Financial Considerations

October 17th 2024

Overview of Idiopathic Pulmonary Fibrosis (IPF)

August 1st 2024

Unmet Needs in IPF Landscape

August 1st 2024

Economic Impact of IPF

August 1st 2024

Key Considerations for Selecting IPF Treatment

Video Interviews
View All
June 17th 2025

COVID-19’s Hidden Toll: Noah Greenspan, DPT, on Inflammation, Flares, and Recovery

December 3rd 2024

Uncovering the Gaps: Study Sheds Light on Racial Disparities in IPF Outcomes

October 16th 2024

Dr Cesar Davila-Chapa Calls for Awareness of Racial Differences in IPF Hospitalization

October 11th 2024

Role of Immunosuppressive Therapies in Managing ILD

September 27th 2024

The Impact of FVC Decline and Lung Function in IPF

September 17th 2024

Promising Clinical Trial Updates in IPF/PPF

August 31st 2024

Dr Martin Kolb Discusses Combination Therapies and the Future of IPF Treatment

August 30th 2024

Helping Patients Understand IPF Diagnosis and Treatment

June 28th 2022

The Role of Lung Transplants in ILD Treatment

June 14th 2022

Treatment Goals for Patients With ILD

Podcasts
View All
December 12th 2024

Managed Care Cast Presents: Navigating Burdens and Treatment Challenges of IPF

More News

Patients in the 60 mg arm had a mean increase in FVC of 98.4 ml while the placebo group had a drop in FVC of 20.3 ml. | Image credit: Angelov - stock.adobe.com
June 14th 2025

AI-Derived Therapy for IPF Shows Potential in Phase 2a Trial

Jared Kaltwasser
The potential therapy for idiopathic pulmonary fibrosis is notable because not only was the small molecule discovered by artificial intelligence, but the drug’s target itself was, too.
Providers reported issues with accessing diagnostic tests, such as laboratory and lung function tests, and limited availability of pulmonary rehabilitation and home oxygen for rural patients. | Image credit: BJP7images - stock.adobe.com
June 7th 2025

Patients With ILD in Rural Areas Face Barriers to Care

AJMC Contributor
While citing overwhelming barriers patients in rural areas face when accessing care, providers noted the potential of telehealth to improve access in a survey.
Patients often managed their treatment on their own, with more than half of patients adjusting the dose of their antifibrotic, either by lowering their dose, skipping doses, or interrupting treatment. | Image Credit: underverse - stock.adobe.com
May 27th 2025

Patients With IPF Face QOL Challenges With Antifibrotic Treatment

AJMC Contributor
Patients reported that side effects often impacted their quality of life (QOL). However, most patients said their treatment helped slow disease progression and gave them hope.
Data from this new study show that cutoffs as low as 2% were associated with poor outcomes in IPF, even when accounting for other known prognostic factors. | Image Credit: Crystal light - stock.adobe.com
May 22nd 2025

Real-World Findings Suggest New Look at Thresholds for IPF Progression

AJMC Contributor
Even a 2% decline in lung function predicted poor outcomes for patients with idiopathic pulmonary fibrosis (IPF) in a new study.
Pill and water in hand | Image credit: New Africa – stock.adobe.com
May 20th 2025

FIBRONEER-ILD: Novel PDE4B Inhibitor Slows FVC Decline in Progressive Pulmonary Fibrosis

Hayden E. Klein
Nerandomilast significantly slowed lung function decline and reduced mortality in patients with progressive pulmonary fibrosis (PPF), with consistent efficacy regardless of background antifibrotic therapy.
Chest x-ray | Image credit: Nadzeya – stock.adobe.com
May 20th 2025

The Last 5 Years: Lessons in Progressive Pulmonary Fibrosis Treatment

Hayden E. Klein
Researchers are working to redefine diagnosis and treatment with data-driven tools aimed at identifying patients earlier and guiding precision care.
Transplant-free survival from the time of right-heart catheterization was also significantly longer in the dual therapy group. | Image Credit: mi_viri - stock.adobe.com
May 15th 2025

Dual Therapy Appears to Benefit Patients With Pulmonary Fibrosis, Pulmonary Hypertension

Jared Kaltwasser
The combination of antifibrotic therapy and pulmonary vasodilator therapy improved transplant-free survival but had no significant impact on exercise capacity in pulmonary fibrosis and pulmonary hypertension.
Nurse talking to Black patient in waiting room | Image credit: DC Studio - stock.adobe.com
May 10th 2025

IPF Trial Practices Often Exclude Certain Patients, Perspectives

Jared Kaltwasser
Clinical trials for idiopathic pulmonary fibrosis could benefit from improved patient engagement to include diverse perspectives and inclusive practices.
Generated image of lungs above a doctor's hand with the words "pulmonary fibrosis"| Image credit: mi_viri - stock.adobe.com
May 7th 2025

Predicting the Course of Progressive Pulmonary Fibrosis With FOT

Jared Kaltwasser
Forced oscillation technique (FOT) can enhance early detection and management of progressive pulmonary fibrosis.
Nerandomilast is an investigational oral, preferential inhibitor of phosphodiesterase 4B that has shown promise in IPF and PPF. | Image credit: Елена Бутусова - stock.adobe.com
February 13th 2025

Nerandomilast Improves Lung Function in Progressive Pulmonary Fibrosis: FIBRONEER-ILD

Rose McNulty
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline at 52 weeks in the phase 3 FIBRONEER-ILD trial.
IPF Top 5 of 2024 | Image Credit: Venngage
December 23rd 2024

Top 5 Most-Read IPF Content of 2024

Brooke McCormick
The top 5 idiopathic pulmonary fibrosis (IPF) articles of 2024 explored topics like the effect of oxygen therapy on health care costs and mortality; delayed diagnoses leading to worse outcomes; new drug trials; the impact of diabetes on pulmonary health; and the growing body of research on macrophages and pulmonary fibrosis.
Man yawning at work | Image Credit: LIGHTFIELD STUDIOS - stock.adobe.com
December 13th 2024

Patients With ILD Face Higher Burden of Fatigue, Excessive Daytime Sleepiness

Brooke McCormick
Patients with interstitial lung disease (ILD) experience significantly higher rates of fatigue and excessive daytime sleepiness than healthy individuals.
Highlights from ERS Congress 2024
December 6th 2024

ICYMI: Highlights From ERS Congress 2024

Brooke McCormick
Top coverage from the European Respiratory Society (ERS) Congress 2024 spanned various topics, including artificial intelligence–powered robots transforming respiratory care and late-breaking findings on an epilepsy drug showing promise for treating obstructive sleep apnea.
Year in Review: Idiopathic Pulmonary Fibrosis
December 4th 2024

Year in Review: Idiopathic Pulmonary Fibrosis

COVID-19 vaccine | Image Credit: M.Rode-Foto - stock.adobe.com
November 30th 2024

COVID-19 Vaccine Improves Mental Health in Patients With IPF

Brooke McCormick
COVID-19 vaccination significantly reduced anxiety and depression in patients with idiopathic pulmonary fibrosis (IPF), improving their mental health one month after the first dose.
Exterior of a hospital | Image Credit: Spiroview Inc. - stock.adobe.com
November 27th 2024

Facility Type Influences Antifibrotic Treatment Rates in Patients With IPF

Brooke McCormick
A study in Japan found that antifibrotic treatment rates for patients with idiopathic pulmonary fibrosis (IPF) varied by medical facility, with higher treatment rates observed in referral hospitals than in general hospitals or clinics.
Depiction of global impact | Image Credit: flashmovie - stock.adobe.com
November 25th 2024

ILD, Pulmonary Sarcoidosis Burden Rose Significantly From 1990 to 2021

Brooke McCormick
The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index.
ILD | Image Credit: PH alex aviles - stock.adobe.com
November 20th 2024

Study Highlights Key RA-ILD Risk Factors, Urges Early Screening

Brooke McCormick
This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
ISM001-055 is a novel drug developed through generative AI biotechnology | image credit: ipopba - stock.adobe.com
November 12th 2024

Novel, AI-Procured ISM001-055 Demonstrates Great Promise for Treatment of IPF

Kyle Munz
The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF).
AJMC Q&A with Dr Maria Padilla | Background image credit: ipopba - stock.adobe.com
November 5th 2024

Key ILD Topics at Mount Sinai’s Advances in Pulmonary Medicine 2024

Brooke McCormick
Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, including the latest diagnosis and treatment protocol advancements, at Advances in Pulmonary Medicine 2024.
IPF written on whiteboard| Image Credit: Vitalii Vodolazskyi - stock.adobe.com
October 30th 2024

Low Pulmonary Rehabilitation, Palliative Care Referrals for Patients With IPF Persist

Brooke McCormick
Despite proven benefits, referrals to pulmonary rehabilitation and palliative care for patients with idiopathic pulmonary fibrosis (IPF) in England remain significantly lower than for other respiratory conditions.
ILD spelled out with wooden blocks | Image Credit: PH alex aviles - stock.adobe.com
October 21st 2024

Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD

Brooke McCormick
Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Different size piles of coin being investigated with a magnifying glass | Image Credit: jirsak - stock.adobe.com
October 17th 2024

Early Intervention, Targeted Strategies Needed to Improve Disparities, Survival in Patients With IPF

Brooke McCormick
Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).
IPF blocks held by person with blue glove | Image Credit: Sviatlana - stock.adobe.com
October 15th 2024

Racial, Ethnic Disparities Persist in the Treatment, Hospitalization of Patients With IPF

Brooke McCormick
Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.
Wooden IPF blocks | Image credit: Sviatlana - stock.adobe.com
September 30th 2024

Advancing Care for Idiopathic Pulmonary Fibrosis (IPF): Evaluating Current Treatments and Emerging Therapies for Improved Patient Outcomes

IPF diagnosis | Image credit: Vitalii Vodolazskyi - stock.adobe.com
September 19th 2024

FIBRONEER-IPF Trial of Nerandomilast Meets Primary End Point

Hayden E. Klein
The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF).
Young man coughing | Image Credit: © Tetiana - stock.adobe.com
September 18th 2024

Chronic Cough in Patients With ILD Linked to Reduced Quality of Life

Kimberly Rath, PharmD
Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic cough in patients with idiopathic pulmonary fibrosis and other interstitial lung diseases.
IPF wooden blocks | Image Credit: Sviatlana - stock.adobe.com
September 15th 2024

Automated Body Composition Analysis Predicts Survival in IPF

Jared Kaltwasser
Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF).
Clinical trial graphic | Image credit: photon_photo – stock.adobe.com
September 10th 2024

Overcoming Failures: Lessons From IPF Clinical Trials in the Past Year

Hayden E. Klein
Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.
AI image of lung fibrosis | Image credit: Oranuch – stock.adobe.com
September 8th 2024

New Findings Highlight the Impact of Lung Function Decline in IPF, PPF

Hayden E. Klein
A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and progressive pulmonary fibrosis (PPF).
123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo